Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | AGER |
| Gene Name: | AGER |
| Protein Full Name: | Advanced glycosylation end product-specific recept |
| Alias: | Receptor for advanced glycosylation end products |
| Mass (Da): | 42803 |
| Number AA: | 404 |
| Locus ID: | 177 |
| COSMIC ID: | AGER |
| Gene location on chromosome: | 6p21.32 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19717 |
| Percent of cancer specimens with mutations: | 0.19 |
| Normal role description: | Advanced glycosylation end product-specific receptor (AGER); normal physiologic function of the pathway controls embryonal growth, myogenesis, and mobilization of immune cells. Ligand binding to AGER leads to activation of the MAPK, JAK/STAT, CDC42, and NF-KB pathways. These pathways are upregulated in inflammatory states. AGER is significantly upregulated in a variety of cancers and correlates with propensity to locally invade surrounding tissue. This underscores the emerging interface between cancer and inflammation |